Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carboxymethylthio-3-(3-Chlorophenyl)-1,2,4-Oxadiazol is an experimental small molecule compound with the chemical formula C10H7ClN2O3S and a molecular weight of approximately 270.69 g/mol. It is a polycyclic aromatic compound containing a benzene ring linked to a 1,2,4‑oxadiazole ring via a carbon-carbon or carbon-nitrogen bond. The compound has been studied as an experimental agent and is not approved for clinical use in any country. Its primary known biological interaction is with the enzyme cystathionine gamma‑lyase in humans; however its pharmacological action remains unclear and no therapeutic indications have been established[1][5]. There are no reported clinical trials or approved uses for this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carboxymethylthio-3-(3-chlorophenyl)-1,2,4-oxadiazol.